TABLE 3.
Antimicrobial susceptibilities of clinical isolates and transconjugants
| Strain (PFGE type, pI of ESBL) | No. of isolates | MIC(s) (μg/ml) or range of MICs
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMPa | PIP | PIP-TAZ | CTX | CTX-CLAV | CAZ | CAZ-CLAV | ATM | ATM-CLAV | FOX | IPM | AK | GN | ||
| K. pneumoniae (a, 5.7) | 1 | >512 | >512 | >512 | 32 | 8 | 256 | 128 | 256 | 64 | 32 | 0.25 | 2 | 128 |
| K. pneumoniae (a, 6.0) | 8 | >512 | >512 | 2–4 | 8–16 | ≤0.03–0.06 | 128 | 0.25–0.5 | 128 | 0.125 | 2–4 | 0.125 | 1–2 | 32, 128 |
| K. pneumoniae (d, 6.0) | 3 | >512 | >512 | 32 | 16 | 0.125–0.25 | 128 | 1 | 256 | 0.25 | 8 | 0.125 | 1 | 32 |
| K. pneumoniae (b2, 6.0) | 2 | >512 | >512 | 4–8 | 16 | 0.06–0.125 | 64–128 | 0.5–1 | 128–256 | 0.125–0.25 | 4–8 | 0.125 | 1 | 32–64 |
| K. pneumoniae (b2, 8.2) | 1 | >512 | 128 | 4 | 8 | 0.125 | 128 | 0.5 | 256 | 0.125 | 4 | 0.125 | 16 | 4 |
| K. pneumoniae (b1, 8.2) | 5 | >512 | 256 | 4–8 | 8–16 | 0.125–0.25 | 128 | 0.5–1 | 256 | 0.125–0.25 | 4–8 | 0.125 | 8–16 | 4–8 |
| K. pneumoniae (c, 8.2) | 2 | >512 | 256 | 16 | 8 | 0.25 | 128–256 | 0.5–1 | 256–512 | 0.125 | 16 | 0.125–0.25 | 8 | 4 |
| K. oxytoca (8.2) | 2 | 512–>512 | 64 | 0.5–1 | 1–2 | ≤0.03 | 8 | 0.125 | 8–16 | ≤0.03 | 1 | 0.125 | 16 | 4–8 |
| K. pneumoniae R+b (6.0) | 11 | >512 | 64–128 | 0.5 | 2–4 | ≤0.03 | 8 | 0.06–0.125 | 8–16 | ≤0.03 | 1–2 | 0.125 | 0.5 | 16–32 |
| K. pneumoniae, K. oxytoca R+ (8.2) | 7 | 256 | 16–32 | 0.5 | 1 | ≤0.03 | 8 | 0.125 | 16 | ≤0.03 | 1–2 | 0.125 | 4–8 | 2 |
| E. coli A15 R− | 2 | ≤0.5 | ≤0.5 | ≤0.03 | ≤0.03 | 0.125 | 0.125 | 0.06 | ≤0.03 | 1 | 0.125 | 0.5 | 0.25 | |
| E. coli ATCC 25922 | 4 | 2 | 2 | 0.06 | ≤0.03 | 0.25 | 0.125 | 0.06 | 0.06 | 4 | 0.125 | 1 | 0.5 | |
a
AMP, ampicillin; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; FOX, cefoxitin; IPM, imipenem; TAZ, tazobactam (4 μg/ml); CLAV, clavulanate (2 μg/ml); AK, amikacin; GN, gentamicin.
b
R+, transconjugants.